We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

QNST:NASDAQQuinStreet, Inc. Analysis

Data as of 2026-06-17 - not real-time

$12.95

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

QuinStreet trades at $12.95, comfortably above its 20‑day ($12.16) and 50‑day ($12.40) moving averages but still below the 200‑day SMA ($13.53), indicating short‑term momentum in a longer‑term downtrend. The RSI of 60 and a bullish MACD histogram (+0.098) suggest the stock retains some upside momentum, while decreasing volume and a bearish trend direction flag potential short‑term weakness near the $12.98 resistance level. On the valuation side, the forward PE of 8.5 and a trailing PE of 11.6 are well under the industry average PE of 17.1, positioning QNST as a clear value play. Revenue surged 28% year‑over‑year to $1.18 B, yet margins remain thin (gross 10.5%, operating 3.9%), highlighting a growth story that is still profit‑constrained. The balance sheet is strong with $102 M cash against $78 M debt (debt‑to‑equity 25%), and ROE stands at an impressive 24%, supporting the analyst consensus of a "strong buy" and a median target of $17.
The market’s extreme greed sentiment (92 on the Fear & Greed Index) and a DCF‑derived fair value of $68.6 imply a massive upside potential, though the 30‑day volatility of 53% and a beta near 1 signal heightened price swings. With no dividend and a payout ratio of zero, investors must rely on capital appreciation. Overall, the stock appears significantly undervalued relative to peers, but investors should monitor the near‑term resistance, volume trends, and broader advertising sector cycles.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering near $12.98 resistance
  • Decreasing trading volume
  • Bearish longer‑term trend despite bullish MACD

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Robust 28% revenue growth
  • Forward PE of 8.5 and strong analyst "strong buy" rating
  • Undervalued relative to industry PE and DCF upside

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • DCF fair value indicating ~46% upside
  • High ROE (24%) and low debt levels
  • Sustained cash generation and expanding performance‑marketing platform

Key Metrics & Analysis

Financial Health

Revenue Growth28.30%
Profit Margin5.53%
P/E Ratio11.6
ROE23.94%
ROA3.68%
Debt/Equity25.26
P/B Ratio2.4
Op. Cash Flow$108.1M
Free Cash Flow$108.5M
Industry P/E17.1

Technical Analysis

TrendBearish
RSI60.2
Support$11.02
Resistance$12.98
MA 20$12.16
MA 50$12.40
MA 200$13.53
MACDBullish
VolumeDecreasing
Fear & Greed Index92.02

Valuation

Fair Value$68.62
Target Price$19.00
Upside/Downside46.72%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.02
Volatility53.58%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.